<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04103567</url>
  </required_header>
  <id_info>
    <org_study_id>PROICM 2019-14-MIR</org_study_id>
    <nct_id>NCT04103567</nct_id>
  </id_info>
  <brief_title>Determination of Microbiological Factors Associated With Poor Response to Neoadjuvant Treatment in Rectal Cancers</brief_title>
  <acronym>MICARE</acronym>
  <official_title>Determination of Microbiological Factors Associated With Poor Response to Neoadjuvant Therapy in Rectal Cancers: Focus on Cyclomodulin-producing Escherichia Coli</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this project is to determine in a non-invasive manner (fecal samples) the
      predictive value of the intestinal microbiota and the presence of genotoxin-producing
      bacteria on the response to radiochemotherapy in rectal cancer. This could lead to a better
      understanding and selection of patients for personalized treatment in rectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rectal cancer is the 8th leading cause of cancer in the world with more than 300,000 deaths
      in 2018. In addition to surgery, neoadjuvant radiochemotherapy has proven its value in
      reducing local recurrences. Evaluation of the response to neoadjuvant treatment (essential
      for the subsequent therapeutic decision but also for the oncological prognosis. It is based
      on rectal magnetic resonance imaging, completed after surgery by anatomopathology. A
      personalised treatment with therapeutic de-escalation or intensification for aggressive
      tumours can be decided depending on the response to Neoadjuvant treatment. Thus, knowledge of
      the predictive factors of response to neoadjuvant treatment would permit to anticipate and
      adapt care.

      The intestinal microbiota is a true microbial organ, playing a major role in maintaining
      intestinal homeostasis. Some bacterial species have been identified and suspected of playing
      a role in colorectal carcinogenesis. Among these species, genotoxin-producing Escherichia
      coli (CPEC) strains such as colibactin (cyclomodulin encoded by the genomic islet pks) are
      preferentially detected in patients with colorectal cancer (CRC), especially the most
      aggressive forms. Recent studies show that the intestinal microbiota is a prognostic factor
      in the response to certain chemotherapies or immunotherapies, but little work has been done
      on its potential influence on the effectiveness of radiotherapy. This suggests the
      possibility of using these biomarkers associated with response to neoadjuvant treatment.

      The objective of this project is to determine in a non-invasive manner (fecal samples) the
      predictive value of the intestinal microbiota and the presence of genotoxin-producing
      bacteria on the response to neoadjuvant radiochemotherapy in rectal cancer. This could lead
      to a better understanding and selection of patients for tailored treatment in rectal cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2020</start_date>
  <completion_date type="Anticipated">November 2027</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The ratio between the proportions of poor response to neoadjuvant radiochemotherapy in populations so-called &quot;exposed&quot; (patients colonized by bacteria producing toxins (cyclomodulin) and unexposed (patients not colonized by bacteria producing toxins</measure>
    <time_frame>About 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of cyclomodulin-Producing Escherichia Coli colonization rate before and after neoadjuvant radiotherapy</measure>
    <time_frame>About 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of cyclomodulin-Producing Escherichia Coli prevalence before and after neoadjuvant radiotherapy</measure>
    <time_frame>About 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of prevalence forming the overall bacterial composition before and after neoadjuvant radiochemotherapy</measure>
    <time_frame>About 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of colonization rate (in addition to cyclomodulin-Producing Escherichia Coli) forming the overall bacterial composition before and after neoadjuvant radiochemotherapy</measure>
    <time_frame>About 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative risk of poor response to neoadjuvant radiochemotherapy in colonized patients with other bacteria (&quot;exposed&quot;) compared to non-colonized patients (&quot;unexposed&quot;)</measure>
    <time_frame>About 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients colonized according to the modality of the clinical variable age</measure>
    <time_frame>About 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients colonized according to the modality of the clinical variable gender</measure>
    <time_frame>About 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients colonized according to the modality of the clinical variable body mass index</measure>
    <time_frame>About 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival in colonized people by the different types of bacteria that form the overall bacterial composition (including cyclomodulin-Producing Escherichia Coli) compared to non-colonized people</measure>
    <time_frame>About 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival in colonized people by the different types of bacteria that form the overall bacterial composition (including cyclomodulin-Producing Escherichia Coli) compared to non-colonized people</measure>
    <time_frame>About 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific survival in colonized people by the different types of bacteria that form the overall bacterial composition (including cyclomodulin-Producing Escherichia Coli) compared to non-colonized people</measure>
    <time_frame>About 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Types of other bacteria forming the overall bacterial composition before neoadjuvant radiochemotherapy</measure>
    <time_frame>About 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Biological collection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal samples collected at different times : During inclusion consultation with surgeon, before and after surgery,
In parallel to this fecal collection, standardized clinical data will be entered into a database</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biological collection</intervention_name>
    <description>Fecal samples collected at different times : during inclusion consultation with surgeon, before and after surgery.</description>
    <arm_group_label>Biological collection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically proven lower and mid-rectal adenocarcinoma at clinical stage II and III

          2. Patient is to receive neoadjuvant treatment by radiochemotherapy (capecitabine 825
             mg/m² twice a day + radiotherapy 50 gy) according to French recommendations

          3. Patient who has signed the informed consent of the study

          4. Male or female ≥ 18 years old 5 ) Appropriate contraceptive measures should be used by
             both men and non-menopausal women before entering the trial until at least 8 weeks
             after the last course of radiochemotherapy. The investigator should inform the patient
             about the contraceptive measures to be used.

        Exclusion Criteria:

          1. Antibiotic treatment at the time or in the month preceding stool sampling

          2. Presence of an ostomy

          3. Previous chemotherapy treatment for rectal cancer

          4. Patient not affiliated to a French social protection system

          5. Patient not in favour of good compliance with treatment for psychological, family,
             social or geographical reasons

          6. Legal incapacity (Patient under curatorship or guardianship)

          7. Prior radiation therapy or pelvic curia in the year prior to inclusion

          8. History of other cancers in the last 5 years (except for in-situ cervical carcinomas
             and non-melanoma skin carcinomas treated optimally)

          9. Pregnant or breastfeeding woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillaume Carrier, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut régional du cancer de Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Pierre Bleuse, MD</last_name>
    <phone>4 67 61 31 02</phone>
    <phone_ext>+33</phone_ext>
    <email>jean-pierre.bleuse@icm.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut régional du Cancer de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <state>Hérault</state>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume Carrier, MD</last_name>
      <phone>4 67 61 25 59</phone>
      <phone_ext>+33</phone_ext>
      <email>guillaume.carrier@icm.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <state>Puy De Dôme</state>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Johan Gagnières, MD</last_name>
      <email>jgagniere@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.</citation>
    <PMID>30207593</PMID>
  </reference>
  <reference>
    <citation>Gérard JP, André T, Bibeau F, Conroy T, Legoux JL, Portier G, Bosset JF, Cadiot G, Bouché O, Bedenne L; Société Française de Chirurgie Digestive (SFCD), Société Française d’Endoscopie Digestive (SFED0), Société Française de Radiothérapie Oncologique (SFRO). Rectal cancer: French Intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). Dig Liver Dis. 2017 Apr;49(4):359-367. doi: 10.1016/j.dld.2017.01.152. Epub 2017 Jan 20.</citation>
    <PMID>28179091</PMID>
  </reference>
  <reference>
    <citation>van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, Rutten HJ, Påhlman L, Glimelius B, van de Velde CJ; Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011 Jun;12(6):575-82. doi: 10.1016/S1470-2045(11)70097-3. Epub 2011 May 17.</citation>
    <PMID>21596621</PMID>
  </reference>
  <reference>
    <citation>Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R; German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004 Oct 21;351(17):1731-40.</citation>
    <PMID>15496622</PMID>
  </reference>
  <reference>
    <citation>Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis. 1997;12(1):19-23.</citation>
    <PMID>9112145</PMID>
  </reference>
  <reference>
    <citation>Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U Jr, Silva e Sousa AH Jr, Campos FG, Kiss DR, Gama-Rodrigues J. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004 Oct;240(4):711-7; discussion 717-8.</citation>
    <PMID>15383798</PMID>
  </reference>
  <reference>
    <citation>Renehan AG, Malcomson L, Emsley R, Gollins S, Maw A, Myint AS, Rooney PS, Susnerwala S, Blower A, Saunders MP, Wilson MS, Scott N, O'Dwyer ST. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol. 2016 Feb;17(2):174-183. doi: 10.1016/S1470-2045(15)00467-2. Epub 2015 Dec 17.</citation>
    <PMID>26705854</PMID>
  </reference>
  <reference>
    <citation>Rullier E, Rouanet P, Tuech JJ, Valverde A, Lelong B, Rivoire M, Faucheron JL, Jafari M, Portier G, Meunier B, Sileznieff I, Prudhomme M, Marchal F, Pocard M, Pezet D, Rullier A, Vendrely V, Denost Q, Asselineau J, Doussau A. Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial. Lancet. 2017 Jul 29;390(10093):469-479. doi: 10.1016/S0140-6736(17)31056-5. Epub 2017 Jun 7.</citation>
    <PMID>28601342</PMID>
  </reference>
  <reference>
    <citation>Rouanet P, Rullier E, Lelong B, Maingon P, Tuech JJ, Pezet D, Castan F, Nougaret S; and the GRECCAR Study Group. Tailored Treatment Strategy for Locally Advanced Rectal Carcinoma Based on the Tumor Response to Induction Chemotherapy: Preliminary Results of the French Phase II Multicenter GRECCAR4 Trial. Dis Colon Rectum. 2017 Jul;60(7):653-663. doi: 10.1097/DCR.0000000000000849.</citation>
    <PMID>28594714</PMID>
  </reference>
  <reference>
    <citation>Savage DC. Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol. 1977;31:107-33. Review.</citation>
    <PMID>334036</PMID>
  </reference>
  <reference>
    <citation>Nougayrède JP, Taieb F, De Rycke J, Oswald E. Cyclomodulins: bacterial effectors that modulate the eukaryotic cell cycle. Trends Microbiol. 2005 Mar;13(3):103-10. Review.</citation>
    <PMID>15737728</PMID>
  </reference>
  <reference>
    <citation>Nougayrède JP, Homburg S, Taieb F, Boury M, Brzuszkiewicz E, Gottschalk G, Buchrieser C, Hacker J, Dobrindt U, Oswald E. Escherichia coli induces DNA double-strand breaks in eukaryotic cells. Science. 2006 Aug 11;313(5788):848-51.</citation>
    <PMID>16902142</PMID>
  </reference>
  <reference>
    <citation>Bonnet M, Buc E, Sauvanet P, Darcha C, Dubois D, Pereira B, Déchelotte P, Bonnet R, Pezet D, Darfeuille-Michaud A. Colonization of the human gut by E. coli and colorectal cancer risk. Clin Cancer Res. 2014 Feb 15;20(4):859-67. doi: 10.1158/1078-0432.CCR-13-1343. Epub 2013 Dec 13.</citation>
    <PMID>24334760</PMID>
  </reference>
  <reference>
    <citation>Buc E, Dubois D, Sauvanet P, Raisch J, Delmas J, Darfeuille-Michaud A, Pezet D, Bonnet R. High prevalence of mucosa-associated E. coli producing cyclomodulin and genotoxin in colon cancer. PLoS One. 2013;8(2):e56964. doi: 10.1371/journal.pone.0056964. Epub 2013 Feb 14.</citation>
    <PMID>23457644</PMID>
  </reference>
  <reference>
    <citation>Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy. Nat Rev Cancer. 2017 May;17(5):271-285. doi: 10.1038/nrc.2017.13. Epub 2017 Mar 17. Review.</citation>
    <PMID>28303904</PMID>
  </reference>
  <reference>
    <citation>Villéger R, Lopès A, Veziant J, Gagnière J, Barnich N, Billard E, Boucher D, Bonnet M. Microbial markers in colorectal cancer detection and/or prognosis. World J Gastroenterol. 2018 Jun 14;24(22):2327-2347. doi: 10.3748/wjg.v24.i22.2327. Review.</citation>
    <PMID>29904241</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 24, 2019</study_first_submitted>
  <study_first_submitted_qc>September 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2019</study_first_posted>
  <last_update_submitted>February 24, 2020</last_update_submitted>
  <last_update_submitted_qc>February 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rectal</keyword>
  <keyword>cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

